LivaNova PLC $LIVN Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. grew its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 890.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 105,059 shares of the company's stock after acquiring an additional 94,457 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.19% of LivaNova worth $4,127,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in LIVN. Wells Fargo & Company MN lifted its stake in shares of LivaNova by 6.0% in the 4th quarter. Wells Fargo & Company MN now owns 220,782 shares of the company's stock valued at $10,224,000 after purchasing an additional 12,517 shares during the period. Envestnet Asset Management Inc. lifted its stake in shares of LivaNova by 15.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock valued at $2,034,000 after purchasing an additional 5,850 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after purchasing an additional 219 shares during the period. Invesco Ltd. lifted its stake in shares of LivaNova by 0.6% in the 4th quarter. Invesco Ltd. now owns 111,374 shares of the company's stock valued at $5,158,000 after purchasing an additional 667 shares during the period. Finally, Renaissance Technologies LLC raised its position in LivaNova by 9.2% during the fourth quarter. Renaissance Technologies LLC now owns 112,594 shares of the company's stock worth $5,214,000 after acquiring an additional 9,500 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LIVN has been the subject of a number of research analyst reports. Barclays reduced their price objective on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research report on Thursday, May 8th. Robert W. Baird upped their price objective on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a research report on Tuesday, May 20th. Needham & Company LLC restated a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research report on Tuesday, May 13th. Finally, Wall Street Zen upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, LivaNova presently has a consensus rating of "Buy" and a consensus price target of $59.29.

LivaNova Stock Down 0.5%

NASDAQ:LIVN traded down $0.27 during mid-day trading on Monday, hitting $53.45. The stock had a trading volume of 149,565 shares, compared to its average volume of 709,010. The stock has a 50-day simple moving average of $45.70 and a two-hundred day simple moving average of $42.81. The company has a market capitalization of $2.92 billion, a PE ratio of -13.73 and a beta of 0.92. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $57.35. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.84 by $0.21. The company had revenue of $352.50 million for the quarter, compared to analysts' expectations of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the company earned $0.93 earnings per share. On average, equities research analysts anticipate that LivaNova PLC will post 2.85 EPS for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.